nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.36485/1561-6274-2024-28-4-9-21QUMKLQnefr-2347Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESЭкстракорпоральные методы гемокоррекции при заболеваниях почек (обзор литературы)Extracorporeal methods of hemocorrection in kidney diseases (literature review)https://orcid.org/0000-0001-6010-9583ФоминА. М.FominA. M.

Проф. Фомин Александр Михайлович, д-р мед наук, отделение хирургической гемокоррекции и детоксикации, ведущий научный сотрудник

120110, Москва, ул. Щепкина, д. 61/2, корп 9

Prof. Aleksander M.Fomin, MD, PhD, DMedSci, Department of Surgical Hemocorrection and Detoxification, senior researcher

120110, Russia, Moscow, Shchepkina St., 61/2, build. 9

amf05@mail.ruМосковский областной научно-исследовательский клинический институт имени М.Ф. ВладимирскогоРоссияMoscow Regional Research Clinical Institute named after M.F. VladimirskyRussian Federation202416012025284921Copyright © Фомин А.М., 20252025Фомин А.М.Fomin A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/2347

Обзор литературы посвящен методам экстракорпоральной гемокоррекции, таким как плазмаобмен, каскадная плазмафильтрация и иммуносорбция при заболеваниях почек, включая гломерулонефрит, ассоциированный с антителами к базальной мембране клубочка, гломерулонефрит, ассоциированный с антинейтрофильными цитоплазматическими антителами, фокально-сегментарный гломерулосклероз, системная красная волчанка, атипичный гемолитикоуремический синдром у взрослых

The literature review is devoted to methods of extracorporeal hemocorrection, such as plasma exchange, cascade plasma filtration and immunosorption in kidney diseases, including glomerulonephritis associated with antibodies to the glomerular basement membrane, antineutrophil cytoplasmic antibodies-associated glomerulonephritis, focal segmental glomerulosclerosis, systemic lupus erythematosus, atypical hemolytic-uremic syndrome in adults

плазмаобменкаскадная плазмафильтрацияиммуносорбциягломерулонефритатипичный гемолитико-уремический синдром у взрослыхplasma exchangecascade plasma filtrationimmunosorptionglomerulonephritisatypical hemolytic-uremic syndrome in adultsReferencesConnelly-Smith L, Alquist CR, Aqui NA et al. Guidelines on the use of therapeutic apheresis in clinical practice – evidencebased approach from th writing committee of the American Society for Apheresis: the Ninth special issue. J Clin Apher 2023;38:77– 278. doi: 10.1002/jca.22043Connelly-Smith L, Alquist CR, Aqui NA et al. Guidelines on the use of therapeutic apheresis in clinical practice – evidencebased approach from th writing committee of the American Society for Apheresis: the Ninth special issue. J Clin Apher 2023;38:77– 278. doi: 10.1002/jca.22043Williams ME, Balogun RA. Principles of separation:indications and therapeutic targets for plasma exchange. Clin J Am Soc Nephrol 2014;9(1):181–190. doi: 10.2215/CJN.04680513Williams ME, Balogun RA. Principles of separation:indications and therapeutic targets for plasma exchange. Clin J Am Soc Nephrol 2014;9(1):181–190. doi: 10.2215/CJN.04680513Pusey CD, Levy JB. Plasmapheresis in immunologic renal disease. Blood Purif 2012;33(1-3):190–198. doi: 10.1159/000334155Pusey CD, Levy JB. Plasmapheresis in immunologic renal disease. Blood Purif 2012;33(1-3):190–198. doi: 10.1159/000334155Hafer C, Golla P, Gericke M et al. Membrane versus centrifuge-based therapeutic plasma exchange: a randomized prospective crossover study. Int UrolNephrol 2016;48(1):133–138. doi: 10.1007/s11255-015-1137-3Hafer C, Golla P, Gericke M et al. Membrane versus centrifuge-based therapeutic plasma exchange: a randomized prospective crossover study. Int UrolNephrol 2016;48(1):133–138. doi: 10.1007/s11255-015-1137-3Yamaji K. Immunoadsorption for collagen and rheumatic diseases. Transfusion and Apheresis Science 2017;56(5):666– 670. doi: 10.1016/j.transci.2017.08.012Yamaji K. Immunoadsorption for collagen and rheumatic diseases. Transfusion and Apheresis Science 2017;56(5):666– 670. doi: 10.1016/j.transci.2017.08.012Hirano R, Namazuda K, Hirata N. Double filtration plasmapheresis: review of current clinical applications. Ther Apher Dial 2021;25(2):145–151. doi: 10.1111/1744-9987.13548Hirano R, Namazuda K, Hirata N. Double filtration plasmapheresis: review of current clinical applications. Ther Apher Dial 2021;25(2):145–151. doi: 10.1111/1744-9987.13548Poullin P, Announ N, Mugnier B et al. Protein A-immunoadsorption (prosorba column) in the treatment of rheumatoid arthritis. Joint Bone Spine 2005;72(2):101–103. doi: 10.1016/j.jbspin.2004.02.009Poullin P, Announ N, Mugnier B et al. Protein A-immunoadsorption (prosorba col-umn) in the treatment of rheumatoid arthritis. Joint Bone Spine 2005;72(2):101–103. doi: 10.1016/j.jbspin.2004.02.009Соколов АА, Мануилов АС, Бардаков СН и др. Программная иммуносорбция с регенерацией сорбционных колонок при лечении волчаночного нефрита. Современная ревматология 2020;14(3):111–116. doi: 10.14412/1996-7012-2020-3-111-116Sokolov AA, Manuilov AS, Bardakov SN et al. Programmed immunoadsorption with regeneration of adsoption columns in the treatment of lupus nephritis. Modern Rheumatology Journal 2020;14(3):111–116. (In Russ.) doi: 10/14412/1996-7012-2020-3-111-116Новые колонки. Брендбук. ООО «НПФ Покард». 16с. Интернет ресурс https://pocard.ru/wp-content/uploads/Broshures/1.%20Брендбук_новые_колонки.pdfNew Columns. Brandbook. LLC «NPF Pocard». 16 p. Internet resource https://pocard.ru/wp-content/uploads/Broshures/1.%20Брендбук_новые_колонки.pdf (In Russ.)Jennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65(1):1–11. doi: 10.1002/ art.37715. doi: 10.1002/art.37715Jennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65(1):1–11. doi: 10.1002/ art.37715. doi: 10.1002/art.37715Kalluri R, Wilson CB, Weber M et al. Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and goodpasture syndrome. J Am Soc Nephrol 1995;6(4):1178–1185. doi: 10.1681/ASN.V641178Kalluri R, Wilson CB, Weber M et al. Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and goodpasture syndrome. J Am Soc Nephrol 1995;6(4):1178–1185. doi: 10.1681/ASN.V641178Levy JB, Hammad T, Coulthart A et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 2004;66(4):1535–1540. doi: 10.1111/j.15231755.2004.00917.xLevy JB, Hammad T, Coulthart A et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 2004;66(4):1535–1540. doi: 10.1111/j.15231755.2004.00917.xJohnson JP, Moore J, Austin HA et al. Therapy of antiglomerular basement membrane antibody disease: Analysis of prognostic significance of clinical, pathologic and treatment factors. Med (United States) 1985;64(4):219–227. doi: 10.1097/00005792-198507000-00003Johnson JP, Moore J, Austin HA et al. Therapy of antiglomerular basement membrane antibody disease: Analysis of prognostic significance of clinical, pathologic and treatment factors. Med (United States) 1985;64(4):219–227. doi: 10.1097/00005792-198507000-00003Kaewput W, Thongprayoon C, Boonpheng B et al. In patient burden and mortality of Goodpasture's syndrome in the United States:nationwide inpatient sample 2003–2014. J Clin Med 2020;9:455. doi: 10.3390/jcm9020455Kaewput W, Thongprayoon C, Boonpheng B et al. In patient burden and mortality of Goodpasture's syndrome in the United States:nationwide inpatient sample 2003–2014. J Clin Med 2020;9:455. doi: 10.3390/jcm9020455Marques C, Carvelli J, Biard L et al. Prognostic Factors in Anti-glomerular Basement Membrane Disease: A Multicenter Study of 119 Patients. Front Immunol 2019;10. doi: 10.3389/fimmu.2019.01665Marques C, Carvelli J, Biard L et al. Prognostic Factors in Anti-glomerular Basement Mem-brane Disease: A Multicenter Study of 119 Patients. Front Immunol 2019;10. doi: 10.3389/fimmu.2019.01665Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001;134(11):1033–1042. doi: 10.7326/0003-4819-134-11200106050-00009Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001;134(11):1033–1042. doi: 10.7326/0003-4819-134-11200106050-00009Rovin BH, Adler SG, Barratt J et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:753–779. doi: 10.1016/j.kint.2021.05.015Rovin BH, Adler SG, Barratt J et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:753–779. doi: 10.1016/j.kint.2021.05.015Lockwood CM, Boulton-Jones JM, Lowenthal RM et al. Recovery from goodpasture’s syndrome after immunosuppressive treatment and plasmapheresis. Br Med J 1975;2(5965):252–254. doi: 10.1136/bmj.2.5965.252Lockwood CM, Boulton-Jones JM, Lowenthal RM et al. Recovery from goodpasture’s syndrome after immunosuppressive treatment and plasmapheresis. Br Med J 1975;2(5965):252–254. doi: 10.1136/bmj.2.5965.252Savage CO, Pusey CD, Bowman C et al. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980–4. Br Med J (Clin Res Ed) 1986;292:301–304. doi: 10.1136/bmj.292.6516.301Savage CO, Pusey CD, Bowman C et al. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980–4. Br Med J (Clin Res Ed) 1986;292:301–304. doi: 10.1136/bmj.292.6516.301Hu W, Liu Z, Ji D et al. Staphylococcal protein a immunoadsorption for goodpasture’s syndrome in four chinese patients. Journal of Nephrology 2006;19(3):312–317Hu W, Liu Z, Ji D et al. Staphylococcal protein a immunoadsorption for goodpas-ture’s syndrome in four chinese patients. Journal of Nephrology 2006;19(3):312–317Laczika K, Knapp S, Derfler K et al. Immunoadsorption in goodpasture’s syndrome. Am J Kidney Dis 2000;36(2):392–395. doi: 10.1053/ajkd.2000.8993Laczika K, Knapp S, Derfler K et al. Immunoadsorption in goodpasture’s syndrome. Am J Kidney Dis 2000;36(2):392–395. doi: 10.1053/ajkd.2000.8993Biesenbach P, Kain R, Derfler K et al. Long-term outcome of anti-glomerular basement membrane antibody disease treated with immunoadsorption. PLoS One 2014;9(7):e103568. doi: 10.1371/journal.pone.0103568Biesenbach P, Kain R, Derfler K et al. Long-term outcome of anti-glomerular base-ment membrane antibody disease treated with immunoadsorption. PLoS One 2014;9(7):e103568. doi: 10.1371/journal.pone.0103568Zhang Y-y, Tang Z, Chen D-M et al. Comparison of double filtration plasmapheresis with immunoadsorption therapy in patients with anti-glomerular basement membrane nephritis. BMC Nephrol 2014;15:128. doi: 10.1186/1471-2369-15-128Zhang Y-y, Tang Z, Chen D-M et al. Comparison of double filtration plasmapheresis with immunoadsorption therapy in patients with anti-glomerular basement membrane nephritis. BMC Nephrol 2014;15:128. doi: 10.1186/1471-2369-15-128Beck LH, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361(1):11–21. doi: 10.1056/NEJMoa0810457Beck LH, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361(1):11–21. doi: 10.1056/NEJMoa0810457Tomas NM, Beck LH, Meyer-Schwesinger C et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014;371(24):2277–2287. doi: 10.1056/NEJMoa1409354Tomas NM, Beck LH, Meyer-Schwesinger C et al. Thrombospondin type-1 do-main-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014;371(24):2277–2287. doi: 10.1056/NEJMoa1409354Sethi S, Debiec H, Madden B et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int 2020;97(1):163–174. doi: 10.1016/j.kint.2019.09.014Sethi S, Debiec H, Madden B et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int 2020;97(1):163–174. doi: 10.1016/j.kint.2019.09.014Sethi S, Madden BJ, Debiec H et al. Exostosin 1/exostosin 2-associated membranous nephropathy. J Am Soc Nephrol 2019;30(6):1123–1136. doi: 10.1681/ASN.2018080852Sethi S, Madden BJ, Debiec H et al. Exostosin 1/exostosin 2-associated membra-nous nephropathy. J Am Soc Nephrol 2019;30(6):1123–1136. doi: 10.1681/ASN.2018080852Xu Z, Chen L, Xiang H et al. Advances in Pathogenesis of Idiopathic Membranous Nephropathy. Kidney Dis 2020:330–345. doi: 10.1159/00050770Xu Z, Chen L, Xiang H et al. Advances in Pathogenesis of Idiopathic Membranous Nephropathy. Kidney Dis 2020:330–345. doi: 10.1159/00050770Ponticelli C, Zucchelli P, Passerini P et al. A 10-year followup of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995;48(5):1600–1604. doi: 10.1038/ki.1995.453Ponticelli C, Zucchelli P, Passerini P et al. A 10-year followup of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995;48(5):1600–1604. doi: 10.1038/ki.1995.453Cattran DC, Appel GB, Hebert LA et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001;59(4):1484–1490. doi: 10.1046/j. 1523-1755.2001.0590041484.xCattran DC, Appel GB, Hebert LA et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001;59(4):1484–1490. doi: 10.1046/j. 1523-1755.2001.0590041484.xBeck L, Bomback AS, Choi MJ et al. KDOQI US commentary on the 2012 KDI-GO clinical practice guideline for glomerulonephritis. Am J Kidney Dis 2013;62(3):403–441. doi: 10.1053/j.ajkd.2013.06.002Beck L, Bomback AS, Choi MJ et al. KDOQI US commentary on the 2012 KDI-GO clinical practice guideline for glomerulonephritis. Am J Kidney Dis 2013;62(3):403–441. doi: 10.1053/j.ajkd.2013.06.002Perna A, Schieppati A, Zamora J et al. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis 2004;44(3):385–401. doi: 10.1053/j.ajkd.2004.05.020Perna A, Schieppati A, Zamora J et al. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis 2004;44(3):385–401. doi: 10.1053/j.ajkd.2004.05.020Muller-Deile J, Schiffer L, Hiss M et al. A new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis. Eur J Clin Invest 2015;45(12):1260– 1269. doi: 10.1111/eci.12545Muller-Deile J, Schiffer L, Hiss M et al. A new rescue regimen with plasma ex-change and rituximab in high-risk membranous glomerulonephritis. Eur J Clin Invest 2015;45(12):1260– 1269. doi: 10.1111/eci.12545Esnault VL, Besnier D, Testa A et al. Effect of protein a immunoadsorption in nephrotic syndrome of various etiologies. J Am Soc Nephrol 1999;10(9):2014–2017. doi: 10.1681/ASN.V1092014Esnault VL, Besnier D, Testa A et al. Effect of protein a immunoadsorption in ne-phrotic syndrome of various etiologies. J Am Soc Nephrol 1999;10(9):2014–2017. doi: 10.1681/ASN.V1092014Hamilton P, Kanigicherla D, Hanumapura P et al. Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in anti-PLA2 R positive primary membranous nephropathy. J Clin Apher 2018;33(3):283–290. doi: 10.1002/jca.21599Hamilton P, Kanigicherla D, Hanumapura P et al. Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in anti-PLA2 R positive prima-ry membranous nephropathy. J Clin Apher 2018;33(3):283–290. doi: 10.1002/jca.21599Eskandary F, Wahrmann M, Biesenbach P et al. ABO antibody and complement depletion by immunoadsorption combined with membrane filtration a randomized, controlled, cross-over trial. Nephrol Dial Transplant 2014;29(3):706–714. doi: 10.1093/ndt/gft502Eskandary F, Wahrmann M, Biesenbach P et al. ABO antibody and complement depletion by immunoadsorption combined with membrane filtration a randomized, con-trolled, cross-over trial. Nephrol Dial Transplant 2014;29(3):706–714. doi: 10.1093/ndt/gft502Weinmann-Menke J, Holtz S, Sollinger D et al. Treatment of membranous nephropathy in patients with THSD7A antibodies using immunoadsorption. Am J Kidney Dis 2019;74(6):849–852. doi: 10.1053/j.ajkd.2019.05.021Weinmann-Menke J, Holtz S, Sollinger D et al. Treatment of membranous nephropa-thy in patients with THSD7A antibodies using immunoadsorption. Am J Kidney Dis 2019;74(6):849–852. doi: 10.1053/j.ajkd.2019.05.021Konigshausen E, Sellin L. Circulating permeability factors in primary focal segmental glomerulosclerosis: areview of proposed candidates. Biomed Res Int 2016;2016:3765608. doi: 10.1155/2016/3765608Konigshausen E, Sellin L. Circulating permeability factors in primary focal segmental glomerulosclerosis: areview of proposed candidates. Biomed Res Int 2016;2016:3765608. doi: 10.1155/2016/3765608Kashgary A, Sontrop J, Li L et al. The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: a systematic review and meta-analysis of 77 case-reports and case-series. BMC Nephrology 2016;17:104. doi: 10.1186/s12882-016-0322-7Kashgary A, Sontrop J, Li L et al. The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: a systematic review and meta-analysis of 77 case-reports and case-series. BMC Nephrology 2016;17:104. doi: 10.1186/s12882-016-0322-7Ren H, Shen P, Li X et al. Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis: a randomized controlled trial. Am J Nephrol 2013;37(1):84–90. doi: 10.1159/000346256Ren H, Shen P, Li X et al. Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis: a randomized con-trolled trial. Am J Nephrol 2013;37(1):84–90. doi: 10.1159/000346256Beer A, Mayer G, Kronbichler A. Treatment strategies of adult primary focal segmental glomerulosclerosis: a systematic review focusing on the last two decades. Biomed Res Int 2016;2016:4192578. doi: 10.1155/2016/4192578Beer A, Mayer G, Kronbichler A. Treatment strategies of adult primary focal seg-mental glomerulosclerosis: a systematic review focusing on the last two decades. Biomed Res Int 2016;2016:4192578. doi: 10.1155/2016/4192578Lau EW, Ma PH, Wu X et al. Mycophenolate mofetil for pri mary focal segmental glomerulosclerosis: systematic review. Ren Fail 2013;35(6):914–929. doi: 10.3109/0886022X.2013.794687Lau EW, Ma PH, Wu X et al. Mycophenolate mofetil for pri mary focal segmental glomerulosclerosis: systematic review. Ren Fail 2013;35(6):914–929. doi: 10.3109/0886022X.2013.794687Hansrivijit P, Cheungpasitporn W, Thongprayoon C et al. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis. BMC Nephrol 2020;21(1):134. doi: 10.1186/s12882-020-01797-7Hansrivijit P, Cheungpasitporn W, Thongprayoon C et al. Rituximab therapy for fo-cal segmental glomerulosclerosis and minimal change disease in adults: a systematic re-view and meta-analysis. BMC Nephrol 2020;21(1):134. doi: 10.1186/s12882-020-01797-7Korbet SM. The treatment of primary focal segmental glomerulosclerosis. Ren Fail 2000;22(6):685–696. doi: 10.1081/jdi-100101956Korbet SM. The treatment of primary focal segmental glomerulosclerosis. Ren Fail 2000;22(6):685–696. doi: 10.1081/jdi-100101956Mitwalli AH. Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis? Nephrol Dial Transplant 1998;13(6):1524–1528. doi: 10.1093/ndt/13.6.1524Mitwalli AH. Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis? Nephrol Dial Transplant 1998;13(6):1524–1528. doi: 10.1093/ndt/13.6.1524Moriconi L, Lenti C, Puccini R et al. Proteinuria in focal segmental glomerulosclerosis: role of circulating factors and therapeutic approach. Ren Fail 2001;23(3-4):533–541. doi: 10.1081/jdi-100104735Moriconi L, Lenti C, Puccini R et al. Proteinuria in focal segmental glomerulosclero-sis: role of circulating factors and therapeutic approach. Ren Fail 2001;23(3-4):533–541. doi: 10.1081/jdi-100104735Muso E, Mune M, Hirano T et al. A prospective observational survey on the long-term effect of LDL apheresis on drugresistant nephrotic syndrome. Nephron Extra 2015;5(2):58–66. doi: 10.1159/000437338Muso E, Mune M, Hirano T et al. A prospective observational survey on the long-term effect of LDL apheresis on drugresistant nephrotic syndrome. Nephron Extra 2015;5(2):58–66. doi: 10.1159/000437338Dirim AB, Demir E, Guller N et al. Efficacy of intravenous combined immunosuppression with plasmapheresis in adult patients with refractory primary focal segmental glomerulosclerosis. J Clin Apher 2022;37:376–387. doi: 10.1002/jca.21985Dirim AB, Demir E, Guller N et al. Efficacy of intravenous combined immunosuppression with plasmapheresis in adult patients with refractory primary focal segmental glomerulosclerosis. J Clin Apher 2022;37:376–387. doi: 10.1002/jca.21985Fencl F, Vondrak K, Rosik T et al. Recurrence of nephrotic proteinuria in children with focal segmental glomoerulosclerosis: early treatment with plasmapheresis and immunoasorption should be associated with better prognosis. Minerva Pediatrica 2016;68:348–335Fencl F, Vondrak K, Rosik T et al. Recurrence of nephrotic proteinuria in children with focal segmental glomoerulosclerosis: early treatment with plasmapheresis and immunoasorption should be associated with better prognosis. Minerva Pediatrica 2016;68:348–335Uffing A, Perez-Saez MJ, Mazzali M et al. Recurrence of FSGS after kidney transplantation in adults. Clin J Am Soc Nephrol 2020;15:247–325. doi: 10.2215/CJN.08970719Uffing A, Perez-Saez MJ, Mazzali M et al. Recurrence of FSGS after kidney transplantation in adults. Clin J Am Soc Nephrol 2020;15:247–325. doi: 10.2215/CJN.08970719Raina R, Krishnappa V, Sanchez-Kazi C et al. Dextransulfate plasma adsorption lipoprotein apheresis in drug resistant primary focal segmental glomerulosclerosis patients: results from a prospective, multicenter, single-arm intervention study. Front Pediatr 2019;7:454. doi: 10.3389/fped.2019.00454Raina R, Krishnappa V, Sanchez-Kazi C et al. Dextransulfate plasma adsorption lipoprotein apheresis in drug resistant primary focal segmental glomerulosclerosis patients: results from a prospective, multicenter, single-arm intervention study. Front Pediatr 2019;7:454. doi: 10.3389/fped.2019.00454Nakazawa D, Masuda S, Tomaru U et al. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol 2019;15(2):91–101. doi: 10.1038/s41584-018-0145-yNakazawa D, Masuda S, Tomaru U et al. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol 2019;15(2):91–101. doi: 10.1038/s41584-018-0145-yYang JJ, Jennette JC, Falk RJ. Immune complex glomerulonephritis is induced in rats immunized with heterologous myeloperoxidase. Clin Exp Immunol 1994;97(3):466–473. doi: 10.1111/j.1365-2249.1994.tb06111.xYang JJ, Jennette JC, Falk RJ. Immune complex glomerulonephritis is induced in rats immunized with heterologous myeloperoxidase. Clin Exp Immunol 1994;97(3):466–473. doi: 10.1111/j.1365-2249.1994.tb06111.xPusey CD, Rees AJ, Evans DJ et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991;40:757–763. doi: 10.1038/ki.1991.272Pusey CD, Rees AJ, Evans DJ et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991;40:757–763. doi: 10.1038/ki.1991.272Jayne DR, Gaskin G, Rasmussen N et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18(7):2180–2188. doi: 10.1681/ASN.2007010090Jayne DR, Gaskin G, Rasmussen N et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18(7):2180–2188. doi: 10.1681/ASN.2007010090Walsh M, Casian A, Flossmann O et al. Long-term followup of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 2013;84:397–402. doi: 10.1038/ki.2013.131Walsh M, Casian A, Flossmann O et al. Long-term followup of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 2013;84:397–402. doi: 10.1038/ki.2013.131Walsh M, Merkel PA, Peh CA et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis (PEXIVAS). N Engl J Med 2020;382(7):622–631. doi: 10.1056/NEJMoa1803537Walsh M, Merkel PA, Peh CA et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis (PEXIVAS). N Engl J Med 2020;382(7):622–631. doi: 10.1056/NEJMoa1803537Derebail VK, Falk RJ. ANCA-associated vasculitis – refining therapy with plasma exchange and glucocorticoids. N Engl J Med 2020;382:671–673. doi: 10.1056/NEJMe1917490Derebail VK, Falk RJ. ANCA-associated vasculitis – refining therapy with plasma exchange and glucocorticoids. N Engl J Med 2020;382:671–673. doi: 10.1056/NEJMe1917490Walsh M, Collister D, Zeng L et al. The effects of plasma exchange inpatients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. BMJ 2022;376:e064604. doi: 10.1136/bmj-2021-064604Walsh M, Collister D, Zeng L et al. The effects of plasma exchange inpatients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. BMJ 2022;376:e064604. doi: 10.1136/bmj-2021-064604Bellos I, Michelakis I, Nikolopoulos D. The role of plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Clinical Rheumatology 2020;40(4):1447– 1456. doi: 10.1007/s10067-020-05390-zBellos I, Michelakis I, Nikolopoulos D. The role of plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Clinical Rheumatology 2020;40(4):1447– 1456. doi: 10.1007/s10067-020-05390-zКлинические практические рекомендации KDIGO 2021 по лечению гломерулярных болезней. Бобкова ИН, Буланов НМ, Захарова ЕВ и др., под общей редакцией ЕВ Захаровой. Нефрология и диализ 2022;24(4):577–874. doi: 10.28996/2618-9801-2022-4-577-874KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases, translation into Russian. Bobkova IN, Bulanov NM, Zakharova EV et al., edited by EV Zakharova. Nephrologу and Dialуsis 2022;24(4):577–874 (In Russ.)Palmer A, Cairns T, Dische F et al. Treatment of rapidly progressive glomerulonephritis by extracorporeal immunoadsorption, prednisolone and cyclophosphamide. Nephrol Dial Transplant 1991;6(8):536–542. doi: 10.1093/ndt/6.8.536Palmer A, Cairns T, Dische F et al. Treatment of rapidly progressive glomerulone-phritis by extracorporeal immunoadsorption, prednisolone and cyclophosphamide. Nephrol Dial Transplant 1991;6(8):536–542. doi: 10.1093/ndt/6.8.536Esnault VL, Testa A, Jayne DR et al. Influence of immunoadsorption on the removal of immunoglobulin G autoantibodies in crescentic glomerulonephritis. Nephron 1993;65:180–184. doi: 10.1159/000187471Esnault VL, Testa A, Jayne DR et al. Influence of immunoadsorption on the removal of immunoglobulin G autoantibodies in crescentic glomerulonephritis. Nephron 1993;65:180–184. doi: 10.1159/000187471Matic G, Michelsen A, Hofmann D et al. Three Cases of C-ANCA-Positive Vasculitis Treated with Immunoadsorption: Possible Benefit in Early Treatment. Therapeutic Apheresis and Dialysis 2001;5(1):68–72. doi: 10.1046/j.1526-0968.2001.005001068.xMatic G, Michelsen A, Hofmann D et al. Three Cases of C-ANCA-Positive Vasculitis Treated with Immunoadsorption: Possible Benefit in Early Treatment. Therapeutic Apheresis and Dialysis 2001;5(1):68–72. doi: 10.1046/j.1526-0968.2001.005001068.xBrocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol 2018;13(2):300–317Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol 2018;13(2):300–317Soejima K, Mimura N, Hirashima M et al. A novel human metalloprotease synthe-sized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem 2001;130(4):475–480. doi: 10.1093/oxfordjournals.jbchem.a003009Soejima K, Mimura N, Hirashima M et al. A novel human metalloprotease synthe-sized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem 2001;130(4):475–480. doi: 10.1093/oxfordjournals.jbchem.a003009Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara medical university during 1998 – 2008. Intern Med 2010;49(1):7–15. doi: 10.2169/internalmedicine.49.2706Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopa-thies across Japan: database of Nara medical university during 1998 – 2008. Intern Med 2010;49(1):7–15. doi: 10.2169/internalmedicine.49.2706Scully M, Hunt BJ, Benjamin S et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012;158(3):323–335. doi: 10.1111/j.1365-2141.2012.09167.xScully M, Hunt BJ, Benjamin S et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012;158(3):323–335. doi: 10.1111/j.1365-2141.2012.09167.xSarode R, Bandarenko N, Brecher ME et al. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher 2014;29(3):148–167. doi: 10.1002/jca.21302Sarode R, Bandarenko N, Brecher ME et al. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher 2014;29(3):148–167. doi: 10.1002/jca.21302Rock GA, Shumak KH, Buskard NA et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325(6):393–397. doi: 10.1056/NEJM199108083250604Rock GA, Shumak KH, Buskard NA et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325(6):393–397. doi: 10.1056/NEJM199108083250604Coppo P, Bussel A, Charrier S et al. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine (Baltimore) 2003;82:27–38. doi: 10.1097/00005792200301000-00003Coppo P, Bussel A, Charrier S et al. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine (Baltimore) 2003;82:27–38. doi: 10.1097/00005792200301000-00003Raval JS, Mazepa MA, Rollins-Raval MA et al. Therapeutic plasma exchange taper does not decrease exacerbations in immune thrombotic thrombocytopenic purpura patients. Transfusion 2020;60:1676–1680. doi: 10.1111/trf.15901Raval JS, Mazepa MA, Rollins-Raval MA et al. Therapeutic plasma exchange taper does not decrease exacerbations in immune thrombotic thrombocytopenic purpura patients. Transfusion 2020;60:1676–1680. doi: 10.1111/trf.15901van Dorland HA, Taleghani MM, Sakai K et al. The international hereditary thrombotic thrombocytopenic purpura registry: key findings at enrollment until 2017. Haematologica 2019;104(10):2107–2115. doi: 10.3324/haematol.2019.216796van Dorland HA, Taleghani MM, Sakai K et al. The international hereditary throm-botic thrombocytopenic purpura registry: key findings at enrollment until 2017. Haematologica 2019;104(10):2107–2115. doi: 10.3324/haematol.2019.216796Cataland SR, Kourlas PJ, Yang S et al. Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura Blood Adv 2017;1(23):2075–2082. doi: 10.1182/bloodadvances.2017009308Cataland SR, Kourlas PJ, Yang S et al. Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura Blood Adv 2017;1(23):2075–2082. doi: 10.1182/bloodadvances.2017009308Scully M, Cataland SR, Peyvandi F et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2019;380(4):335–346. doi: 10.1056/NEJMoa1806311Scully M, Cataland SR, Peyvandi F et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2019;380(4):335–346. doi: 10.1056/NEJMoa1806311Knobl P, Haas M, Laczika K et al. Immunoadsorption for the treatment of a patient with severe thrombotic thrombocytopenic purpura resistant to plasma exchange: kinetics of an inhibitor of ADAMTS13. J Thromb Haemost 2003;1(1):187–189. doi: 10.1046/j.1538-7836.2003.00004.xKnobl P, Haas M, Laczika K et al. Immunoadsorption for the treatment of a patient with severe thrombotic thrombocytopenic purpura resistant to plasma exchange: kinetics of an inhibitor of ADAMTS13. J Thromb Haemost 2003;1(1):187–189. doi: 10.1046/j.1538-7836.2003.00004.xDrew MJ. Resolution of refractory, classic thrombotic thrombocytopenic purpura after staphylococcal protein a immunoadsorption. Transfusion 1994;34(6):536–538. doi: 10.1046/j.1537-2995.1994.34694295072.xDrew MJ. Resolution of refractory, classic thrombotic thrombocytopenic purpura af-ter staphylococcal protein a immunoadsorption. Transfusion 1994;34(6):536–538. doi: 10.1046/j.1537-2995.1994.34694295072.xTarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005;365(9464):1073–1086. doi: 10.1016/S01406736(05)71144-2Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005;365(9464):1073–1086. doi: 10.1016/S01406736(05)71144-2Syed S, Hakala P, Singh AK et al. Role of pneumococcal NanA neuraminidase activity in peripheral blood. Front Cell Infect Microbiol 2019;9:218. doi: 10.3389/fcimb.2019.00218Syed S, Hakala P, Singh AK et al. Role of pneumococcal NanA neuraminidase activity in peripheral blood. Front Cell Infect Microbiol 2019;9:218. doi: 10.3389/fcimb.2019.00218Nathanson S, Kwon T, Elmaleh M et al. Acute neurological involvement in diarrhea associ[ated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2010;5:1218–1228. doi: 10.2215/CJN.08921209Nathanson S, Kwon T, Elmaleh M et al. Acute neurological involvement in diarrhea associ[ated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2010;5:1218–1228. doi: 10.2215/CJN.08921209Menne J, Nitschke M, Stingele R et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012;345:e4565. doi: 10.1136/bmj.e4565Menne J, Nitschke M, Stingele R et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012;345:e4565. doi: 10.1136/bmj.e4565Waters AM, Kerecuk L, Luk D et al. Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience. J Pediatr 2007;151:140–144. doi: 10.1016/j.jpeds.2007.03.055.Waters AM, Kerecuk L, Luk D et al. Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience. J Pediatr 2007;151:140–144. doi: 10.1016/j.jpeds.2007.03.055.Greinacher A, Friesecke S, Abel P et al. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4associated haemolytic uraemic syndrome: a prospective trial. Lancet 2011;378(9797):1166–1173. doi: 10.1016/S01406736(11)61253-1Greinacher A, Friesecke S, Abel P et al. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4associated haemolytic uraemic syndrome: a prospective trial. Lancet 2011;378(9797):1166–1173. doi: 10.1016/S01406736(11)61253-1Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009;361(17):1676–1687. doi: 10.1056/ NEJMra0902814Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009;361(17):1676–1687. doi: 10.1056/ NEJMra0902814Formeck C, Swiatecka-Urban A. Extra-renal manifestations of atypical hemolytic uremic syndrome. Pediatr Nephrol 2018;34:1337–1348. doi: 10.1007/s00467-018-4039-7Formeck C, Swiatecka-Urban A. Extra-renal manifestations of atypical hemolytic uremic syndrome. Pediatr Nephrol 2018;34:1337–1348. doi: 10.1007/s00467-018-4039-7Fremeaux-Bacchi V, Miller EC, Liszewski MK et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008;112(13):4948–4952. doi: 10.1182/blood-2008-01-133702Fremeaux-Bacchi V, Miller EC, Liszewski MK et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008;112(13):4948–4952. doi: 10.1182/blood-2008-01-133702Delvaeye M, Noris M, De Vriese A et al. Thrombomodulin mutations in atypical hemolyticuremic syndrome. N Engl J Med 2009;361(4):345–357. doi: 10.1056/NEJMoa0810739Delvaeye M, Noris M, De Vriese A et al. Thrombomodulin mutations in atypical hemolyticuremic syndrome. N Engl J Med 2009;361(4):345–357. doi: 10.1056/NEJMoa0810739Jozsi M, Licht C, Strobel S et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/ CFHR3 deficiency. Blood 2008;111(3):1512–1514. doi: 10.1182/blood-2007-09-109876Jozsi M, Licht C, Strobel S et al. Factor H autoantibodies in atypical hemolytic ure-mic syndrome correlate with CFHR1/ CFHR3 deficiency. Blood 2008;111(3):1512–1514. doi: 10.1182/blood-2007-09-109876Bayer G, von Tokarski F, Thoreau B et al. Etiologyand outcomes of thrombotic microangiopathies. CJASN 2019;14(4):557– 566. doi: 10.2215/CJN.11470918Bayer G, von Tokarski F, Thoreau B et al. Etiologyand outcomes of thrombotic mi-croangiopathies. CJASN 2019;14(4):557– 566. doi: 10.2215/CJN.11470918Fakhouri F, Hourmant M, Campistol JM et al. Terminal complement inhibitor eculizumab in adultpatients with atypical hemolytic uremic syndrome: a Single-Arm, OpenLabel trial. Am J Kidney Dis 2016;68(1):84–93. doi: 10.1053/j.ajkd.2015.12.034Fakhouri F, Hourmant M, Campistol JM et al. Terminal complement inhibitor eculi-zumab in adultpatients with atypical hemolytic uremic syndrome: a Single-Arm, OpenLabel trial. Am J Kidney Dis 2016;68(1):84–93. doi: 10.1053/j.ajkd.2015.12.034Noris M, Caprioli J, Bresin E et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010;5(10):1844–1859. doi: 10.2215/CJN.02210310Noris M, Caprioli J, Bresin E et al. Relative role of genetic complement abnormali-ties in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010;5(10):1844–1859. doi: 10.2215/CJN.02210310Cao M, Leite BN, Ferreiro T et al. Eculizumab modifies outcomes in adults with atypical hemolytic uremic syndrome with acute kidney injury. Am J Nephrol 2018;48(3):225–233. doi: 10.1159/000492865Cao M, Leite BN, Ferreiro T et al. Eculizumab modifies outcomes in adults with atypical hemolytic uremic syndrome with acute kidney injury. Am J Nephrol 2018;48(3):225–233. doi: 10.1159/000492865Боброва ЛА, Ватазин АВ, Демьянова КА и др. Атипичный гемолитико-уремический синдром». Клинические рекомендации, 2021. https://cr.minzdrav.gov.ru/recomend/550_2Bobrova LA, Vatazin AV, Demyanova KA et al. Atipichnii gemolitiko_uremicheskii sindrom» Klinicheskie rekomendacii, 2021. (In Russ.) https://cr.minzdrav.gov.ru/recomend/550_2Mannik M, Merrill CE, Stamps LD et al. Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J Rheumatol 2003;30(7):1495–1504.Mannik M, Merrill CE, Stamps LD et al. Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J Rheumatol 2003; 30(7):1495–1504Hohenstein B, Bornstein SR, Aringer M. Immunoadsorption for connective tissue disease. Atheroscler Suppl 2013;14(1):185. doi: 10.1016/j.atherosclerosissup.2012.10.034Hohenstein B, Bornstein SR, Aringer M. Immunoadsorption for connective tissue disease. Atheroscler Suppl 2013;14(1):185. doi: 10.1016/j.atherosclerosissup.2012.10.034Jones JV, Cumming RH, Bucknall RC et al. Plasmapheresis in the management of acute systemic lupus erythematosus? Lancet 1976;1(7962):709–711. doi: 10.1016/s0140-6736(76)93088-9Jones JV, Cumming RH, Bucknall RC et al. Plasmapheresis in the management of acute systemic lupus erythematosus? Lancet 1976;1(7962):709–711. doi: 10.1016/s0140-6736(76)93088-9Lewis EJ, Hunsicker LG, Lan SP et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The lupus nephritis collaborative study group. N Engl J Med 1992;326(21):1373– 1379. doi: 10.1056/NEJM199205213262101Lewis EJ, Hunsicker LG, Lan SP et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The lupus nephritis collaborative study group. N Engl J Med 1992;326(21):1373– 1379. doi: 10.1056/NEJM199205213262101Aringer M, Smolen JS, Graninger WB. Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthritis Rheumat 1998;41(3):414–420Aringer M, Smolen JS, Graninger WB. Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthritis Rheumat 1998;41(3):414–420Soyuoz A, Karadag O, Karaagac T et al. Therapeutic plasma exchange for refractory SLE: a comparison of outcomes between different sub-phenotypes. Eur J Rheumatol 2018;5(1):32–36. doi: 10.5152/eurjrheum.2017.17088Soyuoz A, Karadag O, Karaagac T et al. Therapeutic plasma exchange for refracto-ry SLE: a comparison of outcomes between different sub-phenotypes. Eur J Rheumatol 2018;5(1):32–36. doi: 10.5152/eurjrheum.2017.17088Li QY, Yu F, Zhou FD, Zhao MH. Plasmapheresis Is Associated With Better Renal Outcomes in Lupus Nephritis Patients With Thrombotic Microangiopathy: A Case Series Study. Medicine (Baltimore) 2016;95:e3595. doi: 10.1097/MD.0000000000003595Li QY, Yu F, Zhou FD, Zhao MH. Plasmapheresis Is Associated With Better Renal Outcomes in Lupus Nephritis Patients With Thrombotic Microangiopathy: A Case Series Study. Medicine (Baltimore) 2016;95:e3595. doi: 10.1097/MD.0000000000003595Gordon C, Amissah-Arthur MB, Gayed M et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology 2018;57:e1– e45. doi: 10.1093/rheumatology/kex286Gordon C, Amissah-Arthur MB, Gayed M et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology 2018;57:e1– e45. doi: 10.1093/rheumatology/kex286Федеральные клинические рекомендации по диагностике и лечению системной красной волчанки. Ассоциация ревматологов России. 2016 г. – 24с Интернет ресурс: https://rheumatolog.ru/sites/default/files/Pdf/clinrec/sistemnaya_krasnaya_volchanka_doFederalnie klinicheskie rekomendacii po diagnostike i lecheniyu sistemnoi krasnoi volchanki. Associaciya revmatologov Rossii. 2016 g. – 24s (In Russ.) Internet resurs_https://rheumatolog.ru/sites/default/files/Pdf/clinrec/sistemnaya_krasnaya_volchanka_docNeuwelt CM. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther Apher Dial 2003;7:173–182. doi: 10.1046/j.1526-0968.2003.00032.xNeuwelt CM. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther Apher Dial 2003;7:173–182. doi: 10.1046/j.1526-0968.2003.00032.xFanouriakis A, Kostopoulou M, Cheema K et al. 2019 Update of the Joint European League Against Rheumatism and European Reanal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020;79:713–723. doi: 10.1136/annrheumdis-2020-216924Fanouriakis A, Kostopoulou M, Cheema K et al. 2019 Update of the Joint European League Against Rheumatism and European Reanal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020;79:713–723. doi: 10.1136/annrheumdis-2020-216924Stummvoll G, Aringer M, Handisurya A et al. Immunoadsorption in autoimmune diseases affecting the kidney. Semin Nephrol 2017;37(5):478–487. doi: 10.1016/j.semnephrol.2017.05.020Stummvoll G, Aringer M, Handisurya A et al. Immunoadsorption in autoimmune diseases affecting the kidney. Semin Nephrol 2017;37(5):478–487. doi: 10.1016/j.semnephrol.2017.05.020Stummvoll GH, Aringer M, Smolen JS et al. IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis 2005;64(7):1015–1021. doi: 10.1136/ard.2004.029660Stummvoll GH, Aringer M, Smolen JS et al. IgG immunoadsorption reduces sys-temic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis 2005;64(7):1015–1021. doi: 10.1136/ard.2004.029660Gaubitz M, Seidel M, Kummer S et al. Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus. J Autoimmun 1998;11(5):495–501. doi: 10.1006/jaut.1998.0229Gaubitz M, Seidel M, Kummer S et al. Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus. J Autoimmun 1998;11(5):495–501. doi: 10.1006/jaut.1998.0229Yang M, Liao C, Zhu Q et al. Meta-analysis on the efficacy and safety of immunoadsorption for systemic lupus erythematosus among Chinese population. Clin Rheumatol 2020;39:3581–3592. doi: 10.1007/s10067-020-05156-7Yang M, Liao C, Zhu Q et al. Meta-analysis on the efficacy and safety of immunoadsorption for systemic lupus erythematosus among Chinese population. Clin Rheumatol 2020;39:3581–3592. doi: 10.1007/s10067-020-05156-7

The authors declare that there are no conflicts of interest present.